The bigger picture behind the medicine
featured
Science
July 1, 2026
Understanding the Oligonucleotide Market: A Foundation for Next‑Generation API Capabilities
Oligonucleotides drive fastest-growing API segment with 50% of pipelines using oligo-based candidates. Polpharma provides Nusinersen capabilities.
written by
Witold Kozak
,
Antonina Fryś
,
latest stories
Science
June 3, 2026
Digital Twin at Polpharma API: Turning Manufacturing Data into Predictable Value
Digital Twin shifts manufacturing from reactive to preventive strategies. Compare batches against golden batch benchmarks to identify deviations in real time.
written by
Karol Sągol
,
Society
June 3, 2026
Broadening Access: How Generic APIs Are Shaping the Future of SMA Treatment
Spinal muscular atrophy affects 1 in 10,000 live births. Generic API suppliers expand global access to disease-modifying treatments for this genetic disorder.
written by
Antonina Fryś
,
Science
March 23, 2026
Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment
ADCs deliver cytotoxic agents directly to cancer cells using monoclonal antibodies. The global market is projected to reach 27.8 billion USD by 2032.
Science
March 23, 2026
Rising to the Solubility Challenge: Collaborative Solutions in API Development
Poor water solubility affects 90% of new chemical entities. Polpharma API provides collaborative solutions and expertise to overcome formulation barriers.
written by
Dumitru Samohvalov
,
Science
July 22, 2025
An Overview of Breast Cancer: Understanding Risks, Treatments, and Market Trends
Breast cancer is the most common cancer in women, with 2.3 million new cases annually. Learn about genetic, lifestyle and reproductive risk factors.
written by
Antonina Fryś
,
highlights
Science
June 3, 2026
Digital Twin at Polpharma API: Turning Manufacturing Data into Predictable Value
written by
Karol Sągol
,
.avif)
Society
June 3, 2026
Broadening Access: How Generic APIs Are Shaping the Future of SMA Treatment
written by
Antonina Fryś
,
Science
March 23, 2026
Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment
For press and analysts
All the Group's press releases, by email.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Science
July 1, 2026
Understanding the Oligonucleotide Market: A Foundation for Next‑Generation API Capabilities
Oligonucleotides drive fastest-growing API segment with 50% of pipelines using oligo-based candidates. Polpharma provides Nusinersen capabilities.
written by
Witold Kozak
,
Antonina Fryś
,
Science
June 3, 2026
Digital Twin at Polpharma API: Turning Manufacturing Data into Predictable Value
Digital Twin shifts manufacturing from reactive to preventive strategies. Compare batches against golden batch benchmarks to identify deviations in real time.
written by
Karol Sągol
,
Society
June 3, 2026
Broadening Access: How Generic APIs Are Shaping the Future of SMA Treatment
Spinal muscular atrophy affects 1 in 10,000 live births. Generic API suppliers expand global access to disease-modifying treatments for this genetic disorder.
written by
Antonina Fryś
,
Science
March 23, 2026
Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment
ADCs deliver cytotoxic agents directly to cancer cells using monoclonal antibodies. The global market is projected to reach 27.8 billion USD by 2032.
.avif)
Science
March 23, 2026
Rising to the Solubility Challenge: Collaborative Solutions in API Development
Poor water solubility affects 90% of new chemical entities. Polpharma API provides collaborative solutions and expertise to overcome formulation barriers.
written by
Dumitru Samohvalov
,
%2520(1).avif)
Science
July 22, 2025
An Overview of Breast Cancer: Understanding Risks, Treatments, and Market Trends
Breast cancer is the most common cancer in women, with 2.3 million new cases annually. Learn about genetic, lifestyle and reproductive risk factors.
written by
Antonina Fryś
,
Science
June 6, 2025
Rising Prevalence of Cancer and Its Impact on the HP API Market
Cancer cases projected to increase 61% by 2050, driving HPAPI demand in oncology; 25 new cancer drugs launched in 2023 demonstrate market growth.
written by
Magdalena Kuć-Kawczyńska
,
.avif)
Science
October 1, 2024
Addressing Nitrosamine Risks in Pharmaceutical Manufacturing
Nitrosamine risks require careful assessment in pharmaceutical synthesis. Secondary amines can mislead development strategies in API manufacturing.
written by
Maciej Graużenis
,
Adam Hałuszczuk
,
.avif)
Science
September 10, 2024
A Comprehensive Overview and Prognosis of the Diabetes Market
Diabetes affects 537 million adults globally, expected to reach 783 million by 2045. Understand types, treatments and market trends for this chronic disease.
written by
Antonina Fryś
,
Science
December 2, 2022
Liophilization: What does a strawberry have in common with Polpharma API?
Polpharma implements freeze-drying technology to produce Isavuconazonium sulfate API on semi-technical scale whilst preserving quality.
written by
Tomasz Zasiewski
,
Science
September 5, 2022
Safe approach in delivering nitrosamine-free API products
Polpharma API ensures nitrosamine-free products through rigorous regulatory controls, protecting patients from carcinogenic impurities.
written by
Karina Boszko
,
Work & Culture
June 7, 2021
Searching for new, better, and innovative solutions. Digital Transformation at Polpharma API.
Polpharma API transforms operations through Industry 4.0, integrating technology with organisational change for manufacturing excellence.
written by
Damian Bogacki
,
Mateusz Godzisz
,
Science
September 10, 2020
Why particles size is important in pharmaceutical industry? Is it really problematic?
Particle size affects drug solubility and bioavailability. 80% of promising molecules rejected due to poor solubility from crystal size.
written by
Robert Rynkiewicz
,
Dorota Pogoda
,
Małgorzata Kujawa
,
Dumitru Samohvalov
,